-
Impact of Using Telehealth in Primary Care on Healthcare Resource Utilization, Costs, and Medication Adherence in Diabetic Patients
Mar 10, 2025, 14:00 PM -
Cost-Effectiveness of Pembrolizumab as First-Line Treatment for Patients with Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) Unresectable or Metastatic Colorectal Cancer (CRC) from Public Payer Perspective in Brazil
Mar 10, 2025, 14:00 PM -
Global, Regional, and National Burdens of Type 1 and Type 2 Diabetes Mellitus in Adolescents from 1990 to 2021, with Forecasts to 2030: A Systematic Analysis of the Global Burden of Disease Study 2021
Mar 10, 2025, 14:00 PM -
Healthcare Resource Utilization Associated With Myotonic Dystrophy Type 1 With Complex Care Needs: Results From the Real-World IMPaCT Study
Mar 10, 2025, 14:00 PM -
Clinical and Economic Benefits of Branched Endovascular Stent Grafting for Intact Thoracoabdominal Aortic Aneurysm Repair: A Real-World Data Analysis
Mar 10, 2025, 14:00 PM -
Consumption and Expenditure of WHO Essential Medicines for Cancer: Drug Utilization Analysis of 40 Countries and Regions from 2012 to 2022
Mar 10, 2025, 14:00 PM -
Psychometric Evaluation of the Mastocytosis Symptom Severity Daily Diary (MS2D2) Instrument in Patients with Nonadvanced Systemic Mastocytosis (NonAdvSM)
Mar 10, 2025, 14:00 PM -
Dinutuximab Beta Versus Naxitamab in the Treatment of Relapsed/ Refractory Neuroblastoma – Matching-Adjusted Indirect Treatment Comparison and Economic Evaluation in the Private Health Insurance System in Brazil
Mar 10, 2025, 14:00 PM -
Evaluating the Association Between Medicare Star Ratings Part D Medication Adherence Measures and the Part C Plan All-Cause Readmission Outcome Measure
Mar 10, 2025, 14:00 PM -
A Reanalysis of Canada's Drug Agency (CDA) Reports: Do Conclusions from Cost-Effectiveness Analyses Using Quality-Adjusted Life-Years (QALYs) Hold When Evaluating with Equal Value of Life-Years Gained (evLYG)?
Mar 10, 2025, 14:00 PM -
Examining Factors Contributing to Age of Late-Onset Autoimmune Disease in U.S. Adults Using Hierarchical Clustering Mechanisms
Mar 10, 2025, 14:00 PM -
Presenteeism in Employees with Chronic Conditions: An Analysis Using Linked Claims and Self-Reported Employee Health Risk Assessment Data
Mar 10, 2025, 14:00 PM -
Prenatal Exposure to Antiseizure Medication and Risk of Adverse Obstetrical Outcomes: A Population-Based Study
Mar 10, 2025, 14:00 PM -
JAV-RARAS: Analysis of Adherence to Clinical Protocols and Therapeutic Guidelines (PCDT) for Rare Diseases – A Comparison of Real-World Clinical Practice in the Context of the Value-Based Care Journey for RARAS.
Mar 10, 2025, 14:00 PM -
Optimized Treatment Sequences for ALK+ Stage IV NSCLC: Cost-Effectiveness Analysis From RCT data and Real-World Evidence
Mar 10, 2025, 14:00 PM -
How Disease Modifying Therapy Utilization In Multiple Sclerosis Is Influenced by Insurance and Out-Of-Pocket Cost in US Adults: A Summary Of Recent Literature
Mar 10, 2025, 14:00 PM -
Cost-Effectiveness of Sotagliflozin for Patients With Type 1 Diabetes and Chronic Kidney Disease, With and Without Dynamic Pricing
Mar 10, 2025, 14:00 PM -
Economic Burden of Prader-Willi Syndrome Among Pediatric Patients in the United States
Mar 10, 2025, 14:00 PM -
The Reimbursement Status of Ustekinumab Across HTAs: A Global Perspective
Mar 10, 2025, 14:00 PM -
Transfusion Needs For Patients With Myelofibrosis In Latin America
Mar 10, 2025, 14:00 PM
